The purpose of this study is to investigate the combination of the antibody-drug conjugate gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with Acute Myeloid Leukemia (AML).
This trial is sponsored by the University of Pittsburgh. 
- Condition: Acute Myeloid Leukemia (AML)
- Phase: I & II
- Estimated Enrollment: 56
- Start: September 2008
- Estimated Completion: April 2011
- Last verified: April 2011
Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.